Hemoperfusion with the HA330/HA380 Cartridge in Intensive Care Settings: A State-Of-The-Art Review

Abstract

Hemoperfusion with the HA330/HA380 cartridge have markedly evolved during the past decade, and has thus been widely used in intensive care settings to treat critical or hyperinflammatory illnesses. A large number of clinical studies have demonstrated that HA330/HA380 hemoperfusion might mitigate systemic inflammatory response syndrome and organ dysfunction in ICU patients by removing inflammatory mediators and metabolic toxins from the blood. However, there is currently lacking a systematic evaluation on the safety and efficacy of HA330/HA380 hemoperfusion in intensive care settings. We are thus motivated to perform a state-of-the-art review of HA330/HA380 hemoperfusion to advance its use in daily critical care practice. In this paper, we first discuss the basic technique characteristics and ex vivo investigations of the HA330/HA380 cartridge. Then, we extensively summarize the latest clinical evidence regarding the use of HA330/HA380 hemoperfusion for the treatment of sepsis, severe COVID-19, cardiac surgery, acute pancreatitis, liver failure, and blunt trauma in sequence. Finally, drug clearance by the HA330/HA380 cartridge is also highlighted to address its safety concerns.